Skip to content
lifestyle.clientim.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Pharvaris N.V.
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
October 8, 2026
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
October 5, 2026
Pharvaris: Deucrictibant XR HAE Prophylaxis Study Meets Primary Endpoint
September 8, 2026
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
September 3, 2026
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
August 6, 2026
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
May 29, 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 21, 2026
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 12, 2026
1
2
Next Page
→